Innovent Releases Results of a Phase 3 Clinical Study of IBI

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022 - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

China , Wanzhen , Jiangsu , Taiwan , United States , Hong Kong , Macau , Suzhou , Chinese , American , Innovent Biologics , Adimab Incyte , Yujie Zhou , Eli Lilly , American Cardiology Association Annual Congress , Prnewswire Innovent Biologics Inc , China Cardiovascular Health , Capital Medical University , Md Anderson Cancer Center , American College Of Cardiology Annual Congress , Company Codes , Incyte Corporation , American College , Cardiology Annual Congress , Vice President , Anzhen Hospital , Lei Qian , Cardiovascular Health , Disease Report , Three Registration Clinical Studies , Main Board , Stock Exchange , Hong Kong Limited , Cancer Center , Mainland China , Resume , Careers , Nnovent Releases Results Ofa Phase 3 Clinical Study Of Ibi306 Pcsk 9 Inhibitor In Chinese Patients With Heterozygous Familial Hypercholesterolemia At The American College Cardiology Annual Congress 2022 , Iospace , Advice ,